18 december 2017: Een reviewstudie en meta analyse ( Green tea and the risk of prostate cancer ) naar de effecten van groene thee als preventie van prostaatkanker en PSA waarden bevestigt dat dagelijks enkele koppen groene thee drinken prostaatkanker kan voorkomen en PSA waarden binnen normaal kan houden.
Conclusie van de onderzoekers:
Voorzover ons bekend is dit de eerste meta-analyse van de consumptie van groene thee-catechinen en de incidentie van prostaatkanker (PCa). Ook voerden we een dosis-respons-meta-analyse uit om systematisch en kwantitatief de associatie van groene thee-inname met PCa-risico te evalueren. Onze nieuwe gegevens toonden aan dat consumptie van groene thee de incidentie van PCa met een lineair dosisresponseffect kan verminderen en dat een inname van meer dan 7 kopjes / dag het PCa-risico significant verlaagde en groene theecatechinen mogelijk effectief zijn om PCa te voorkomen.
Onderaan artikel referentielijst behorend bij deze reviewstudie
Hier de grafiek uit die reviewstudie over het risico op prostaatkanker:
Figure 2
Forest plot for the association of highest versus lowest category of green tea intake and PCa. The association was indicated as RR with the corresponding 95% CI. The RR estimate of each study is marked with a solid black square. The size of the square represents the weight that the corresponding study exerts in the meta-analysis. The CIs of pooled estimates are displayed as a horizontal line through the diamond. RR < 1 indicates decreased risk of PCa. CI = confidence interval, PCa = prostate cancer, RR = relative risk
2 november 2012: Groene thee heeft mits goed gezet en de juiste groene verse thee gebruikt een hoog gehalte van polyfenolen, is gemakkelijk te maken en in te nemen en is op grote schaal beschikbaar. In het boek Eten tegen Kanker kunt u lezen hoe groene thee te maken en welke soorten het beste zijn.
23 november 2006: Bron: 1: Cancer Res. 2006 Jan 15;66(2):1234-40.
Opnieuw bewijst groene thee sterk preventief tegen kanker te zijn bij mannen met een sterk vergroot risico op prostaatkanker door aanwezigheid van afwijkingen aan de prostaat welke vaak leiden tot prostaatkanker. Als vervolg op een soortgelijke studie uit 2005 werd een nieuwe 1 jarige gerandomiseerde placebo gecontroleerde studie opgezet met opnieuw 60 mannen met een sterk vergroot risico op prostaatkanker. Uit de groep die groene thee kreeg te drinken ontwikkelde slechts 1 man prostaatkanker (3%). In de placebogroep kregen negen mannen prostaatkanker. (30%) Een statistisch significant verschil in effectiviteit en bevestigt de resultaten uit de studie uit 2005.
Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study.
Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A.
Department of Medicina Sperimentale, Sezione di Biochimica, University of Parma, Via Volturno 39, 43100 Parma, Italy. saverio.bettuzzi@unipr.it
Green tea catechins (GTCs) proved to be effective in inhibiting cancer growth in several experimental models. Recent studies showed that 30% of men with high-grade prostate intraepithelial neoplasia (HG-PIN) would develop prostate cancer (CaP) within 1 year after repeated biopsy. This prompted us to do a proof-of-principle clinical trial to assess the safety and efficacy of GTCs for the chemoprevention of CaP in HG-PIN volunteers. The purity and content of GTCs preparations were assessed by high-performance liquid chromatography [(-)-epigallocathechin, 5.5%; (-)-epicatechin, 12.24%; (-)-epigallocatechin-3-gallate, 51.88%; (-)-epicatechin-3-gallate, 6.12%; total GTCs, 75.7%; caffeine, <1%]. Sixty volunteers with HG-PIN, who were made aware of the study details, agreed to sign an informed consent form and were enrolled in this double-blind, placebo-controlled study. Daily treatment consisted of three GTCs capsules, 200 mg each (total 600 mg/d). After 1 year, only one tumor was diagnosed among the 30 GTCs-treated men (incidence, approximately 3%), whereas nine cancers were found among the 30 placebo-treated men (incidence, 30%). Total prostate-specific antigen did not change significantly between the two arms, but GTCs-treated men showed values constantly lower with respect to placebo-treated ones. International Prostate Symptom Score and quality of life scores of GTCs-treated men with coexistent benign prostate hyperplasia improved, reaching statistical significance in the case of International Prostate Symptom Scores. No significant side effects or adverse effects were documented. To our knowledge, this is the first study showing that GTCs are safe and very effective for treating premalignant lesions before CaP develops. As a secondary observation, administration of GTCs also reduced lower urinary tract symptoms, suggesting that these compounds might also be of help for treating the symptoms of benign prostate hyperplasia.
PMID: 16424063 [PubMed - indexed for MEDLINE]
In summary, our meta-analysis indicated green tea intake might reduce the incidence of PCa with a linear dose–response effect and decrease PCa risk significantly with over 7 cups/day. This was further confirmed by the potential protective effect of green tea catechins on PCa. Further prospective study with accurate measurement of green tea intake is required to substantiate these conclusions.
Green tea and the risk of prostate cancer
A systematic review and meta-analysis
Yuming Guo, MD,
a Fan Zhi, MD,
b Ping Chen, MD,
a Keke Zhao, MD,
a Han Xiang, MD,
a Qi Mao, MD,
a Xinghuan Wang, MD, PhD,
a and
Xinhua Zhang, MD, PhD
a,∗
Monitoring Editor: Sumit Arora.
Abstract
Prostate cancer (PCa) now remains the 2nd most frequently diagnosed cancer. In recent years, chemoprevention for PCa becomes a possible concept. Especially, many phytochemicals rich foods are suggested to lower the risk of cancer. Among these foods, green tea is considered as effective prevention for various cancers. However, clinical trials and previous meta-analyses on the relationship between green tea consumption and the risk of PCa have produced inconsistent outcomes. This study aims to determine the dose–response association of green tea intake with PCa risk and the preventive effect of green tea catechins on PCa risk. Seven observational studies and 3 randomized controlled trials were retrieved from Cochrane Library, PubMed, Sciencedirect Online, and hand searching. The STATA (version 12.0) was applied to analyze the data. The relative risks (RRs) and 95% confidence intervals were pooled by fixed or random effect modeling. Dose–response relations were evaluated with categories of green tea intake. Although there was no statistical significance in the comparison of the highest versus lowest category, there was a trend of reduced incidence of PCa with each 1 cup/day increase of green tea (P = 0.08). Our dose–response meta-analysis further demonstrated that higher green tea consumption was linearly associated with a reduced risk of PCa with more than 7 cups/day. In addition, green tea catechins were effective for preventing PCa with an RR of 0.38 (P = 0.02). In conclusion, our dose–response meta-analysis evaluated the association of green tea intake with PCa risk systematically and quantitatively. And this is the first meta-analysis of green tea catechins consumption and PCa incidence. Our novel data demonstrated that higher green tea consumption was linearly reduced PCa risk with more than 7 cups/day and green tea catechins were effective for preventing PCa. However, further studies are required to substantiate these conclusions.
References
[1]
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–108. [PubMed][2]
Canby-Hagino ED, Thompson IM. Mechanisms of disease: prostate cancer – a model for cancer chemoprevention in clinical practice. Nat Clin Pract Oncol 2005;2:255–61. [PubMed][3]
Butt MS, Ahmad RS, Sultan MT, et al. Green tea and anticancer perspectives: updates from last decade. Crit Rev Food Sci Nutr 2015;55:792–805. [PubMed][4]
Chen P, Zhang W, Wang X, et al. Lycopene and risk of prostate cancer: a systematic review and meta-analysis. Medicine 2015;94:e1260. [PMC free article] [PubMed][5]
Higdon JV, Frei B. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 2003;43:89–143. [PubMed][6]
Bettuzzi S, Brausi M, Rizzi F, et al. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006;66:1234–40. [PubMed][7]
Chuu CP, Chen RY, Kokontis JM, et al. Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells. Cancer Lett 2009;275:86–92. [PMC free article] [PubMed][8]
Yang JG, Yu HN, Sun SL, et al. Epigallocatechin-3-gallate affects the growth of LNCaP cells via membrane fluidity and distribution of cellular zinc. J Zhejiang Univ Sci B 2009;10:411–21. [PMC free article] [PubMed][9]
Sartor L, Pezzato E, Donà M, et al. Prostate carcinoma and green tea: (−)epigallocatechin-3-gallate inhibits inflammation-triggered MMP-2 activation and invasion in murine TRAMP model. Int J Cancer 2004;112:823–9. [PubMed] Liao S, Umekita Y, Guo J, et al. Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Lett 1995;96:239–43. [PubMed]
Kurahashi N, Sasazuki S, Iwasaki M, et al. Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol 2008;167:71–7. [PubMed]
Jian L, Lee AH, Binns CW. Tea and lycopene protect against prostate cancer. Asia Pac J Clin Nutr 2007;16Suppl 1:453–7. [PubMed]
Montague JA, Butler LM, Wu AH, et al. Green and black tea intake in relation to prostate cancer risk among Singapore Chinese. Cancer Causes Control 2012;23:1635–41. [PMC free article] [PubMed]
Kikuchi N, Ohmori K, Shimazu T, et al. No association between green tea and prostate cancer risk in Japanese men: the Ohsaki Cohort Study. Br J Cancer 2006;95:371–3. [PMC free article] [PubMed]
Allen NE, Sauvaget C, Roddam AW, et al. A prospective study of diet and prostate cancer in Japanese men. Cancer Causes Control 2004;15:911–20. [PubMed]
Zheng J, Yang B, Huang T, et al. Green tea and black tea consumption and prostate cancer risk: an exploratory meta-analysis of observational studies. Nutr Cancer 2011;63:663–72. [PubMed]
Lin YW, Hu ZH, Wang X, et al. Tea consumption and prostate cancer: an updated meta-analysis. World J Surg Oncol 2014;12:38. [PMC free article] [PubMed]
Fei X, Shen Y, Li X, et al. The association of tea consumption and the risk and progression of prostate cancer: a meta-analysis. Int J Clin Exp Med 2014;7:3881–91. [PMC free article] [PubMed]
Yu F, Jin Z, Jiang H, et al. Tea consumption and the risk of five major cancers: a dose-response meta-analysis of prospective studies. BMC Cancer 2014;14:197. [PMC free article] [PubMed]
Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987;9:1–30. [PubMed]
Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 1992;135:1301–9. [PubMed]
Orsini N, Li R, Wolk A, et al. Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. Am J Epidemiol 2012;175:66–73. [PMC free article] [PubMed]
Yoshimura I. The effect of measurement error on the dose-response curve. Environ Health Perspect 1990;87:173–8. [PMC free article] [PubMed]
Berroukche A, Bendahmane M, Kandouci BA. Association of diet with the risk of prostate cancer in Western Algeria. Oncologie 2012;14:674–8.
Sonoda T, Nagata Y, Mori M, et al. A case-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet. Cancer Sci 2004;95:238–324. [PubMed]
Jian L, Xie LP, Lee AH, et al. Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int J Cancer 2004;108:130–5. [PubMed]
Kumar NB, Pow-Sang J, Egan KM, et al. Randomized, placebo-controlled trial of green tea catechins for prostate cancer prevention. Cancer Prev Res (Phila) 2015;8:879–87. [PMC free article] [PubMed]
Brausi M, Rizzi F, Bettuzzi S. Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur Urol 2008;54:472–3. [PubMed]
Kapetanovic IM, Crowell JA, Krishnaraj R, et al. Exposure and toxicity of green tea polyphenols in fasted and non-fasted dogs. Toxicology 2009;260:28–36. [PMC free article] [PubMed]
Johnson R, Bryant S, Huntley AL. Green tea and green tea catechin extracts: an overview of the clinical evidence. Maturitas 2012;73:280–7. [PubMed]
Asghar Z, Masood Z. Evaluation of antioxidant properties of silymarin and its potential to inhibit peroxyl radicals in vitro. Pak J Pharm Sci 2008;21:249–54. [PubMed]
Anesini C, Ferraro GE, Filip R. Total polyphenol content and antioxidant capacity of commercially available tea (Camellia sinensis) in Argentina. J Agric Food Chem 2008;56:9225–9. [PubMed]
Ren F, Zhang S, Mitchell SH, et al. Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene 2000;19:1924–32. [PubMed]
Harper CE, Patel BB, Wang J, et al. Epigallocatechin-3-Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action. Prostate 2007;67:1576–89. [PubMed]
Liao S, Hiipakka RA. Selective inhibition of steroid 5 alpha-reductase isozymes by tea epicatechin-3-gallate and epigallocatechin-3-gallate. Biochem Biophys Res Commun 1995;214:833–8. [PubMed]
Kao YH, Hiipakka RA, Liao S. Modulation of endocrine systems and food intake by green tea epigallocatechin gallate. Endocrinology 2000;141:980–7. [PubMed]
Thomas F, Patel S, Holly JM, et al. Dihydrotestos-terone sensitises LNCaP cells to death induced by epigallocatechin-3-Gallate (EGCG) or an IGF-I receptor inhibitor. Prostate 2009;69:219–24. [PubMed]
Kazi A, Smith DM, Zhong Q, et al. Inhibition of bcl-x(l) phosphorylation by tea polyphenols or epigallocatechin-3-gallate is associated with prostate cancer cell apoptosis. Mol Pharmacol 2002;62:765–71. [PubMed]
Bettuzzi S, Davalli P, Astancolle S, et al. Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens. Cancer Res 2000;60:28–34. [PubMed]
Leskov KS, Klokov DY, Li J, et al. Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 2003;278:11590–600. [PubMed]
Pezzato E, Sartor L, Dell’Aica I, et al. Prostate carcinoma and green tea: PSA-triggered basement membrane degradation and MMP-2 activation are inhibited by (−)epigallocatechin-3-gallate. Int J Cancer 2004;112:787–92. [PubMed]
Siddiqui IA, Malik A, Adhami VM, et al. Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene 2008;27:2055–63. [PubMed]
Adhami VM, Siddiqui IA, Ahmad N, et al. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res 2004;64:8715–22. [PubMed]
Siddiqui IA, Zaman N, Aziz MH, et al. Inhibition of CWR22Rnu1 tumor growth and PSA secretion in athymic nude mice by green and black teas. Carcinogenesis 2006;27:833–9. [PubMed]
Inoue-Choi M, Yuan JM, Yang CS, et al. Genetic association between the COMT genotype and urinary levels of tea polyphenols and their metabolites among daily green tea drinkers. Int J Mol Epidemiol Genet 2010;1:114–23. [PMC free article] [PubMed]
Articles from Medicine are provided here courtesy of Wolters Kluwer Health
complementair, polyfenolen, groene thee, prostaatkanker, epigallocatechinegallaat, EGCG, progressievrij, preventie, PSA waarden
Gerelateerde artikelen
Plaats een reactie ...
Reageer op "Prostaatkanker: Groene thee bewijst opnieuw therapeutische waarde voor prostaatkanker - 27% verschil in ontwikkelen van prostaatkanker tussen placebo en groene thee gebruik- in gerandomiseerde studie bij 60 mannen met vergroot riscio op prostaatkanker"